(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(2.16%) $83.11
(1.98%) $1.752
(1.90%) $2 254.80
(1.41%) $25.10
(1.45%) $922.85
(0.36%) $0.927
(0.73%) $10.85
(0.13%) $0.792
(0.15%) $92.58
@ $91.30
Issued: 27 Mar 2024 @ 11:56
Return: 3.90%
Previous signal: Mar 26 - 11:38
Previous signal:
Return: 2.47 %
Live Chart Being Loaded With Signals
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...
Stats | |
---|---|
Today's Volume | 602 986 |
Average Volume | 814 908 |
Market Cap | 5.81B |
EPS | $0 ( 2024-02-15 ) |
Next earnings date | ( $-1.650 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.33 |
ATR14 | $2.23 (2.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Albers Jeffrey W. | Sell | 11 033 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Buy | 10 000 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Sell | 2 730 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Sell | 6 251 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Buy | 15 073 | Common Stock |
INSIDER POWER |
---|
37.01 |
Last 100 transactions |
Buy: 592 922 | Sell: 279 297 |
Volume Correlation
Blueprint Medicines Corp Correlation
10 Most Positive Correlations | |
---|---|
ACBA | 0.958 |
MANH | 0.953 |
PUCK | 0.951 |
VIRI | 0.949 |
GXII | 0.947 |
AEAC | 0.946 |
ESLT | 0.946 |
RAM | 0.946 |
IVCB | 0.945 |
SKYW | 0.945 |
10 Most Negative Correlations | |
---|---|
PEAR | -0.951 |
VORB | -0.949 |
INFN | -0.934 |
MKTX | -0.931 |
BHTG | -0.928 |
FEMY | -0.927 |
IVAC | -0.926 |
EDUC | -0.926 |
TRIT | -0.925 |
OBNK | -0.924 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Blueprint Medicines Corp Correlation - Currency/Commodity
Blueprint Medicines Corp Financials
Annual | 2023 |
Revenue: | $249.38M |
Gross Profit: | $224.92M (90.19 %) |
EPS: | $-8.37 |
Q4 | 2023 |
Revenue: | $71.96M |
Gross Profit: | $70.17M (97.51 %) |
EPS: | $-1.820 |
Q3 | 2023 |
Revenue: | $56.57M |
Gross Profit: | $52.01M (91.95 %) |
EPS: | $-2.20 |
Q2 | 2023 |
Revenue: | $57.57M |
Gross Profit: | $55.25M (95.96 %) |
EPS: | $-2.19 |
Financial Reports:
No articles found.
Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators